Mobile PSA : A Novel Telehealth Tool for Prostate Cancer Follow-Up

Show full item record



Bergroth , R , Matikainen , M & Rannikko , A 2021 , ' Mobile PSA : A Novel Telehealth Tool for Prostate Cancer Follow-Up ' , European urology open science , vol. 28 , pp. 43-46 .

Title: Mobile PSA : A Novel Telehealth Tool for Prostate Cancer Follow-Up
Author: Bergroth, Robin; Matikainen, Mika; Rannikko, Antti
Contributor: University of Helsinki, Urologian yksikkö
University of Helsinki, HUS Abdominal Center
University of Helsinki, HUS Abdominal Center
Date: 2021-06
Language: eng
Number of pages: 4
Belongs to series: European urology open science
ISSN: 2666-1691
Abstract: The prevalence of prostate cancer (PCa) is increasing. As the prognosis of PCa continues to improve, the increasing follow-up requirements after radical prosta-tectomy or radiotherapy puts significant pressure on health care systems. Follow-up is typically conducted by treating urologists, specialized nurses, or general practitioners. Despite the increase in patient numbers, resources are not likely to increase in proportion. Furthermore, the ongoing COVID-19 pandemic has led to a paradigm shift in our thinking towards telehealth solutions, primarily to avoid or limit physical contact and to spare resources. Here we report our novel telehealth solution for PCa follow-up, called Mobile PSA. Currently, more than 4500 PCa patients have been using Mobile PSA follow-up in our center. Mobile PSA can increase follow-up accuracy, as all biochemical relapses will be detected in a timely manner, can significantly reduce delays in reporting prostate-specific antigen results to patients, and can significantly reduce costs. Patient summary: We assessed a new telehealth information system for prostate cancer follow-up that does not use an app. More than 4500 prostate cancer patients in our center have used this system, called Mobile PSA, for follow-up. The system significantly reduces delays in reporting prostate-specific antigen (PSA) test results to patients, increases the accuracy of detecting recurrence of elevated PSA, and reduces costs. (c) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (
Subject: Telemedicine
Prostate-specific antigen
Prostate cancer
3126 Surgery, anesthesiology, intensive care, radiology
3122 Cancers

Files in this item

Total number of downloads: Loading...

Files Size Format View
Mobile_PSA_A_No ... state_Cancer_Follow_Up.pdf 1.320Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record